Selvita S.A. (SLV) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 May, 2026Executive summary
Achieved 7% year-over-year growth in group commercial revenues and 24% increase in EBITDA, with a 19% EBITDA margin for 2025.
Resource optimization and lean management initiatives delivered a PLN 2m positive EBIT impact in H2 2025, with expected total savings of PLN 27m in 2026.
Secured PLN 112m in grant funding for 2025-2029, including PLN 51m for new service development.
2026 outlook is positive but backlog growth remains modest at +0.3% year-over-year as of March.
Financial highlights
2025 commercial revenues reached PLN 362.9m, up 7% from 2024.
EBITDA rose to PLN 69.0m (+24% YoY), with profitability improving to 18.6%.
Organic commercial revenues grew 4% YoY, with a 20% organic EBITDA margin.
Adjusted EBITDA increased 28% YoY, excluding PLN 2.7m in one-off costs.
FX movements negatively impacted revenues by approximately PLN 8.5m.
Outlook and guidance
Q1 2026 revenues estimated at PLN 78-82m, with an EBITDA margin of 13-16%.
2026 backlog as of March up 0.3% YoY, with a 5.4 percentage point improvement since January.
Contracting activity in Q2-Q3 2026 will be decisive for full-year results.
PLN 27m in cost savings expected in 2026 from resource optimization.
Latest events from Selvita S.A.
- Revenue and EBITDA grew, with cost savings and backlog supporting future outlook.SLV
Q3 202520 Nov 2025 - Revenue down 1% YoY to PLN 342.2m; 2025 backlog up 11%; PozLab acquired; audit unqualified.SLV
Q4 202417 Nov 2025 - H1 2025 saw 18% revenue growth, higher EBITDA, and cost-saving measures amid market recovery.SLV
Q2 202518 Sep 2025 - Revenue down, net loss posted, but Drug Development and 2025 backlog show strong growth.SLV
Q3 202413 Jun 2025 - Net loss, lower revenue, and Pozlab acquisition reshape Selvita's H1 2024 financials.SLV
Q2 202413 Jun 2025 - Q1 2025 revenue up 19% YoY to PLN 91.2m; net loss narrows, operating profit positive.SLV
Q1 20256 Jun 2025